I.V. pain and on the features and use of Zingo for their pediatric
patients. These initiatives will be complemented by Zingo co-promotion
and distribution partner Sagent Pharmaceuticals' representatives, who
will work primarily with hospital pharmacies.
-- Launched two initiatives aimed to improve peripheral venous access pain
management in children: RN VOICE (Registered Nurses for Venipuncture
Optimization through Increased Comfort and Education), a
multidisciplinary group of healthcare professionals led by nurses to
facilitate better management of venous access pain; and
http://www.manageIVpain.com, an interactive Web site designed for
parents and healthcare providers seeking to better manage peripheral
venous access pain in children.
-- Proceeded with plans to file a supplemental New Drug Application with
the FDA in the first quarter of 2008 to expand the Zingo label to
include adults, based on successful pivotal Phase 3 trial in
approximately 700 adult patients.
-- Signed exclusive license agreement with Sigma-Tau SpA for the marketing
and distribution of Zingo in six European countries: Italy, France,
Germany, Netherlands, Belgium and Luxembourg. Sigma-Tau will oversee
all necessary regulatory filings, and will be responsible for all
marketing and sales of Zingo in their territory.
-- Granted an exclusive license to Medical Futures, Inc. for the marketing
and distribution of Zingo in Canada. Under the terms of the license,
Medical Futures will be responsible for all regulatory filings,
marketing, distribution and sales in Canada.
-- Conducted webcast and briefing in New York City with financial analysts
and major investors to present plans for
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved